Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

296.25 -0.25 (-0.08%)
Streaming Delayed Price Updated: 1:28 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Here's How Much You Would Have Made Owning Medpace Hldgs Stock In The Last 5 Years
Via Benzinga
How Is The Market Feeling About Medpace Hldgs?
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
Via Benzinga
A Glimpse Into The Expert Outlook On Medpace Hldgs Through 6 Analysts
Via Benzinga
Here's How Much You Would Have Made Owning Medpace Hldgs Stock In The Last 5 Years
Via Benzinga
(MEDP) - Analyzing Medpace Hldgs's Short Interest
Via Benzinga
$100 Invested In Medpace Hldgs 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Decoding 5 Analyst Evaluations For Medpace Hldgs
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,800 Today
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,500 Today
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
MEDP Stock Earnings: Medpace Hldgs Beats EPS, Misses Revenue for Q1 2024
MEDP stock results show that Medpace Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
$100 Invested In This Stock 5 Years Ago Would Be Worth $700 Today
Via Benzinga
Peering Into Medpace Hldgs's Recent Short Interest
Via Benzinga
Assessing Medpace Hldgs: Insights From 4 Financial Analysts
Via Benzinga
Earnings Scheduled For April 22, 2024
Companies Reporting Before The Bell • MainStreet Bancshares (NASDAQ:MNSB) is projected to report quarterly earnings at $0.52 per share on revenue of $17.10 million. 
Via Benzinga
Uber Leads Five Stocks Near Buy Points
Five resilient stocks are setting up or flirting with entries. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
$1000 Invested In Medpace Hldgs 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Medpace Hldgs: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Medpace Hldgs
Via Benzinga
Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months
Thermo Fisher stock has risen more than 40% since October. Additionally, it's closed higher nine of the past 11 trading sessions. 
Via Investor's Business Daily
Agilent Technologies Stock Getting Closer To Key Technical Benchmark
Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71. 
Via Investor's Business Daily
Uber To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's How Much $100 Invested In Medpace Hldgs 5 Years Ago Would Be Worth Today
Via Benzinga
Peering Into Medpace Hldgs's Recent Short Interest
Via Benzinga
Earnings Scheduled For February 12, 2024
Companies Reporting Before The Bell • Beasley Broadcast Group (NASDAQ:BBGI) is projected to report quarterly loss at $0.07 per share on revenue of $66.05 million. 
Via Benzinga
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks. 
Via InvestorPlace
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.